Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT06395012 | A First-In-Human Study of LY3985297 in Healthy Participants | PHASE1 | COMPLETED | 140 | — | — | Jun 7, 2024 | Aug 6, 2025 | Sep 11, 2025 | 2 | United States |
A summary of TEAEs, SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported in the reported adverse events module
| Arm | Type | Description |
|---|---|---|
| Part A: LY3985297 (Cohorts 1-8) | EXPERIMENTAL | Single ascending dose of LY3985297 administered either intravenously (IV) or subcutaneously (SC). Cohort 5,6 and 7 is conducted in Japanese or Chinese participants. |
| Part B: LY3985297 (Cohorts 1-4) | EXPERIMENTAL | Multiple ascending dose of LY3985297 administered either IV or SC. |
| Placebo Comparator: Part A and B: Placebo | PLACEBO_COMPARATOR | Placebo administered either IV or SC. |
| Name | Type | Description |
|---|---|---|
| LY3985297 | DRUG | Administered either IV or SC. |
| Placebo | DRUG | Administered either IV or SC. |
Inclusion Criteria: * Participants must be overtly healthy, as determined by medical evaluation. * Have a body mass index of 18.0 to 32.0 kilograms per square meter (kg/m²), inclusive, and a minimum body weight of 45.0 kg. * Participants must be assigned male or female at birth and not of childbear...